PMID- 35646146
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Ta-Xi-San Suppresses Atopic Dermatitis Involved in Multitarget Mechanism Using 
      Experimental and Network Pharmacology Analysis.
PG  - 8441938
LID - 10.1155/2022/8441938 [doi]
LID - 8441938
AB  - Atopic dermatitis (AD) is a relapsing and chronic skin inflammation with a common 
      incidence worldwide. Ta-Xi-San (TXS) is a Chinese herbal formula usually used for 
      atopic dermatitis in clinic; however, its active compounds and mechanisms of 
      action are still unclear. Our study was designed to reveal the pharmacological 
      activities, the active compounds, and the pharmacological mechanisms of TXS for 
      atopic dermatitis. Mice were induced by 2,4-dinitrocluorobenzene (DNCB) to build 
      atopic dermatitis model. The pathological evaluation, enzyme-linked immunosorbent 
      assay (ELISA), and hematoxylin and eosin (H&E) assay were performed. The 
      UPLC-Q-Exactive-MS(E) and network pharmacology analysis were performed to explore 
      active ingredients and therapeutic mechanisms of TXS. TXS treatment decreased 
      levels of immunoglobulin E (IgE), interleukin-4 (IL-4), and tumor necrosis 
      factor-alpha (TNF-alpha) in serum induced by DNCB. TXS reduced scratching behavior and 
      alleviated inflammatory pathology of skin and ear. Meanwhile, TXS decreased the 
      spleen index and increased spleen index. The UPLC-Q-Exactive-MS(E) results showed 
      that 65 compounds of TXS were detected and 337 targets were fished. We collected 
      1371 AD disease targets, and the compound-target gene network reveled that the 
      top 3 active ingredients were (-)-epigallocatechin gallate, apigenin, and 
      esculetin, and the core target genes were PTGS2, PTGS1, and HSP90AA1. The KEGG 
      pathway and GO analysis showed that TXS remedied atopic dermatitis via PI3K-Akt 
      signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, and 
      Toll-like receptor (TLR) signaling pathway with the regulation of inflammatory 
      response and transcription. Further, we found that the targets of PTGS2 and 
      HSP90AA1 were both elevated in ears and skin of AD model mouse; however, TXS 
      decreased the elevated expressions of PTGS2 and HSP90AA1. Our study revealed that 
      TXS ameliorated AD based on (-)-epigallocatechin gallate, apigenin, and esculetin 
      via targeting PTGS2 and HSP90AA1.
CI  - Copyright (c) 2022 Wenbing Zhi et al.
FAU - Zhi, Wenbing
AU  - Zhi W
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
FAU - Li, Chun
AU  - Li C
AD  - Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 
      China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
AD  - Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 
      China.
FAU - Zhao, Yiding
AU  - Zhao Y
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
FAU - Zong, Shiyu
AU  - Zong S
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
FAU - Liu, Qiqi
AU  - Liu Q
AD  - Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 
      China.
FAU - Zhou, Jie
AU  - Zhou J
AD  - Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 
      China.
FAU - Wang, Chunliu
AU  - Wang C
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
FAU - Sun, Tingting
AU  - Sun T
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
FAU - Liu, Yang
AU  - Liu Y
AUID- ORCID: 0000-0003-1501-1725
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
FAU - Li, Ye
AU  - Li Y
AUID- ORCID: 0000-0001-5537-4569
AD  - Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese 
      Medicine Hospital), Xi'an 710003, China.
AD  - Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220518
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9132654
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/06/02 06:00
MHDA- 2022/06/02 06:01
PMCR- 2022/05/18
CRDT- 2022/06/01 11:32
PHST- 2021/12/21 00:00 [received]
PHST- 2022/04/08 00:00 [revised]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/06/01 11:32 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/02 06:01 [medline]
PHST- 2022/05/18 00:00 [pmc-release]
AID - 10.1155/2022/8441938 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 May 18;2022:8441938. doi: 
      10.1155/2022/8441938. eCollection 2022.